Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BLM | P54132 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.46 |
| ▸ | POLB | P06746 | 3/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.46 |
| ▸ | MEN1 | O00255 | 2/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | USP2 | O75604 | 1/20 | 0.46 |
| ▸ | EGFR | P00533 | 1/20 | 0.46 |
| ▸ | FYN | P06241 | 1/20 | 0.46 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | HPGD | P15428 | 1/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | APEX1 | P27695 | 1/20 | 0.46 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.46 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.46 |
| ▸ | MTOR | P42345 | 1/20 | 0.46 |
| ▸ | RECQL | P46063 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL427046 | 1.00 | BLM (0.50) | BLMALDH1A1KDM4EPOLBCYP1A2 | |
| SCHEMBL4562897 | 0.81 | RIPK1 (0.47) | BLMALDH1A1KDM4EPOLBCYP1A2 | |
| SCHEMBL29521900 | 0.81 | BLM (0.49) | BLMALDH1A1KDM4EPOLBCYP1A2 | |
| SCHEMBL12679276 | 0.81 | BLM (0.49) | BLMALDH1A1KDM4EPOLBCYP1A2 | |
| SCHEMBL427855 | 0.81 | BLM (0.49) | BLMALDH1A1KDM4EPOLBCYP1A2 | |
| SCHEMBL28690512 | 0.81 | BLM (0.49) | BLMALDH1A1KDM4EPOLBCYP1A2 | |
| SCHEMBL427854 | 0.81 | BLM (0.49) | BLMALDH1A1KDM4EPOLBCYP1A2 | |
| Hydrochloric Acid SCHEMBL3618830 | 0.79 | BLM (0.50) | BLMALDH1A1KDM4EPOLBCYP1A2 | |
| Hydrochloric Acid SCHEMBL3618833 | 0.79 | BLM (0.50) | BLMALDH1A1KDM4EPOLBCYP1A2 | |
| SCHEMBL27207977 | 0.77 | BLM (0.42) | BLMALDH1A1KDM4EPOLBCYP1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 93 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200399311-A1 | NOVEL PEPTIDE BASED PCSK9 VACCINE | ZYDUS LIFESCIENCES LIMITED (IN) | 2020-12-24 | — | — | US | claimed |
| EP-3609532-A1 | NOVEL PEPTIDE BASED PCSK9 VACCINE | Cadila Healthcare Limited (IN) | 2020-02-19 | — | — | EP | claimed |
| CN-110536696-A | PCSK9 vaccine based on new peptide | CADILA HEALTHCARE LTD | 2019-12-03 | — | — | CN | claimed |
| WO-2018189705-A1 | NOVEL PEPTIDE BASED PCSK9 VACCINE | CADILA HEALTHCARE LIMITED (IN) | 2018-10-18 | — | — | WO | claimed |
| US-8883963-B2 | Peptidomimetics with glucagon antagonistic and GLP 1 agonistic activities | CADILA HEALTHCARE LIMITED (IN) | 2014-11-11 | — | — | US | claimed |
| US-8841413-B2 | Antidiabetic compounds | CADILA HEALTHCARE LIMITED (IN) | 2014-09-23 | — | — | US | claimed |
| US-20130225488-A1 | Antidiabetic Comppounds | CADILA HEALTHCARE LIMITED (IN) | 2013-08-29 | — | — | US | claimed |
| EP-2084182-B1 | ANTIDIABETIC COMPOUNDS | CADILA HEALTHCARE LTD (IN) | 2013-08-28 | — | — | EP | claimed |
| US-8383581-B2 | Short-chain peptides as parathyroid hormone (PTH) receptor agonist | CADILA HEALTHCARE LIMITED (IN) | 2013-02-26 | — | — | US | claimed |
| US-20120264685-A1 | SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP 1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST | CADILA HEALTHCARE LIMITED (IN) | 2012-10-18 | — | — | US | claimed |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2008-02-21 | — | — | US | claimed |
| EP-1883652-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | Bristol-Myers Squibb Company (US) | 2008-02-06 | — | — | EP | claimed |
| WO-2007140284-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-12-06 | — | — | WO | claimed |
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY | 2007-10-11 | — | — | US | claimed |
| WO-2007082264-A2 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-07-19 | — | — | WO | claimed |
| EP-1773877-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | Bristol-Myers Squibb Company (US) | 2007-04-18 | — | — | EP | claimed |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-25 | — | — | US | claimed |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | claimed |
| WO-2006127948-A2 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-11-30 | — | — | WO | claimed |
| WO-2006014287-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES AND RELATED CONDITIONS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2006-02-09 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070238669-A1 | HUMAN GLUCAGON-LIKE-PEPTIDE-1 MODULATORS AND THEIR USE IN THE TREATMENT OF DIABETES RELATED CONDITIONS | GLP1R, GIPR, IAPP | BLM 4646/4885ALDH1A1 4570/4885KDM4E 2717/4885 |
| US-20070021346-A1 | N-terminally modified GLP-1 receptor modulators | GLP1R, GIPR, IAPP | BLM 4246/4885ALDH1A1 4813/4885KDM4E 2276/4885 |
| US-20060287242-A1 | Human glucagon-like-peptide-1 modulators and their use in treatment of diabetes and related conditions | GLP1R, GIPR, IAPP | BLM 4624/4885ALDH1A1 4630/4885KDM4E 2660/4885 |
| US-20130225488-A1 | Antidiabetic Comppounds | GLP1R, GPR119, GIPR | BLM 3564/4885ALDH1A1 4147/4885KDM4E 4266/4885 |
| US-20120264685-A1 | SHORT CHAIN PEPTIDOMIMETICS BASED ORALLY ACTIVE GLP 1 AGONIST AND GLUCAGON RECEPTOR ANTAGONIST | GIPR, GLP1R, DPP4 | BLM 4330/4885ALDH1A1 2704/4885KDM4E 1885/4885 |
| US-20080045461-A1 | N-TERMINALLY MODIFIED GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, IAPP | BLM 4271/4885ALDH1A1 4829/4885KDM4E 2366/4885 |
| US-20200399311-A1 | NOVEL PEPTIDE BASED PCSK9 VACCINE | PCSK9, PCSK7, PCSK6 | BLM 3368/4885ALDH1A1 4683/4885KDM4E 3848/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.